Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:GRAC: human PDE2A selective inhibitorMore data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:GRAC: human IMPase 1 inhibitorMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair